Dr. James M. Grichnik, MD

Dr. Grichnik practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Grichnik's NPI, 1740363902, was assigned on October 23, 2006. Dr. Grichnik graduated from Harvard Medical School in 1990. Dr. Grichnik holds Florida license ME102502.

Dr. Grichnik's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Grichnik also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Grichnik's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Grichnik to 1 more breast imaging center, 1 hospital outpatient department and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grichnik practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Grichnik's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Grichnik is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Grichnik's licenses on file in 2 states: Florida and North Carolina.

Dmand AI lists benign or precancerous skin growths, contact dermatitis, rash, scalp rash and skin cyst among the conditions Dr. Grichnik treats.

CMS data shows 857 Medicare services from Dr. Grichnik across 10 procedure codes in 2024, for 208 Medicare patients. Medicare paid $29,463 for them.

CMS counts 208 Medicare patients who saw Dr. Grichnik in 2024. The largest group is 65 to 74, with 108 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Grichnik's median patient age at 72, with 44% women.

In 2024, Dr. Grichnik wrote 131 Medicare Part D claims for 57 patients. 97% of them were for generic drugs. CMS names the drug for 67 of them, across 3 drugs with 11 or more claims each, at $2,282 in total drug cost. In 2023, CMS named 69 claims across 4 drugs.

Dmand AI links 105 papers to Dr. Grichnik, published from 2009 to 2024. 2023 was the busiest year, with 8. The most frequent topics are Skin Neoplasms, Melanoma and Melanocytes. Dr. Grichnik has published most often in J Am Acad Dermatol. Dr. Grichnik's most frequent co-authors are Ashfaq A. Marghoob, MD, Andrew Louis Ross, MD and Allan C. Halpern, MD.

Dmand AI links Dr. Grichnik to 12 clinical trials, 5 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Grichnik that name 3 trials.

CMS Open Payments shows 56 general payments to Dr. Grichnik from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $4,740. It also lists 23 research payments totaling $99,863 from 2019 to 2025, naming 3 clinical trials.

Dmand AI lists 5 awards for Dr. Grichnik, most recently America's Top Doctors in 2014.

Dr. Grichnik graduated from Harvard Medical School in 1990.

Dr. Grichnik is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.